Investors sold shares of Medtronic PLC (NYSE:MDT) on strength during trading hours on Thursday. $79.90 million flowed into the stock on the tick-up and $117.63 million flowed out of the stock on the tick-down, for a money net flow of $37.73 million out of the stock. Of all companies tracked, Medtronic had the 0th highest net out-flow for the day. Medtronic traded up $0.62 for the day and closed at $94.74
A number of research firms have weighed in on MDT. Oppenheimer reissued a “buy” rating on shares of Medtronic in a report on Friday, September 21st. BMO Capital Markets raised their price objective on shares of Medtronic from $94.00 to $104.00 and gave the stock an “outperform” rating in a report on Wednesday, August 22nd. Royal Bank of Canada raised their price objective on shares of Medtronic to $104.00 and gave the stock an “outperform” rating in a report on Wednesday, August 22nd. Argus raised their price objective on shares of Medtronic from $108.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, October 8th. Finally, Zacks Investment Research raised shares of Medtronic from a “hold” rating to a “buy” rating and set a $105.00 price objective on the stock in a report on Tuesday, October 23rd. Seven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $102.58.
The company has a current ratio of 2.46, a quick ratio of 2.06 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $127.11 billion, a PE ratio of 19.49, a P/E/G ratio of 2.50 and a beta of 0.94.
Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 21st. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. The business had revenue of $7.38 billion for the quarter, compared to analyst estimates of $7.24 billion. Medtronic had a net margin of 10.56% and a return on equity of 12.98%. The company’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period last year, the firm posted $1.12 earnings per share. Analysts forecast that Medtronic PLC will post 5.12 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, October 19th. Stockholders of record on Friday, September 28th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.12%. Medtronic’s dividend payout ratio (DPR) is presently 41.93%.
In related news, EVP Michael J. Coyle sold 145,544 shares of Medtronic stock in a transaction on Wednesday, August 22nd. The shares were sold at an average price of $95.50, for a total value of $13,899,452.00. Following the transaction, the executive vice president now directly owns 190,680 shares in the company, valued at approximately $18,209,940. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Richard Kuntz sold 47,176 shares of Medtronic stock in a transaction on Tuesday, August 28th. The shares were sold at an average price of $95.88, for a total transaction of $4,523,234.88. Following the completion of the transaction, the senior vice president now owns 152,579 shares in the company, valued at $14,629,274.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 268,678 shares of company stock worth $25,818,353. 0.28% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the stock. Ballew Advisors Inc purchased a new stake in shares of Medtronic during the 2nd quarter worth $100,000. Fort L.P. purchased a new stake in shares of Medtronic during the 2nd quarter worth $121,000. Global Trust Asset Management LLC boosted its position in shares of Medtronic by 112.1% during the 2nd quarter. Global Trust Asset Management LLC now owns 1,523 shares of the medical technology company’s stock worth $130,000 after purchasing an additional 805 shares in the last quarter. Polaris Greystone Financial Group LLC boosted its position in shares of Medtronic by 255.1% during the 3rd quarter. Polaris Greystone Financial Group LLC now owns 1,321 shares of the medical technology company’s stock worth $130,000 after purchasing an additional 949 shares in the last quarter. Finally, Trustcore Financial Services LLC boosted its position in shares of Medtronic by 97.3% during the 2nd quarter. Trustcore Financial Services LLC now owns 1,760 shares of the medical technology company’s stock worth $151,000 after purchasing an additional 868 shares in the last quarter. Hedge funds and other institutional investors own 80.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Traders Sell Shares of Medtronic (MDT) on Strength (MDT)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/10/traders-sell-shares-of-medtronic-mdt-on-strength-mdt.html.
Medtronic Company Profile (NYSE:MDT)
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Featured Article: Why do corrections happen?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.